Interleukins-4, -5, and -13: Emerging therapeutic targets in allergic disease

Paul S. Foster, Margarita Martinez-Moczygemba, David P. Huston, David B. Corry

Research output: Contribution to journalReview articlepeer-review

69 Scopus citations


For the first time, allergic diseases have emerged as major public health concerns. Highly effective therapies for allergic disease now exist, but are plagued by serious side effects and the fact that a significant minority of patients remains unresponsive. Studies from many laboratories have established that T helper type 2 (TH2) cytokines contribute importantly to diseases such as asthma, and therapeutic strategies that target the key TH2 cytokines are of potential benefit in allergic disease. In this article, we will review the biology of the TH2 cytokines interleukin (IL)-4, IL-5, and IL-13 and their receptors, and will consider several novel strategies to neutralize these molecules in human and experimental asthma. While promising, newer therapies face a gauntlet of developmental challenges, but offer the hope of reducing allergic diseases once again to minor public health concerns.

Original languageEnglish (US)
Pages (from-to)253-264
Number of pages12
JournalPharmacology and Therapeutics
Issue number3
StatePublished - Jul 22 2002


  • Allergic disease
  • Asthma
  • Cytokine
  • Interleukin
  • Receptor
  • T helper type 2 cell

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Interleukins-4, -5, and -13: Emerging therapeutic targets in allergic disease'. Together they form a unique fingerprint.

Cite this